anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current study was designed to investigate the alleviative effect of lactoferrin interventions against the hepatotoxicity induced by titanium dioxide nanoparticles (TiO2-NPs). Thirty male Wistar rats were divided into six groups with 5 rats in each group. The first and second groups were intragastrically administered normal saline and TiO2-NPs (100 mg/kg body weight) as the negative control (NC) and TiO2-NP groups. The third, fourth, and fifth groups were intragastrically administered lactoferrin at concentrations of 100, 200, and 400 mg/kg body weight in addition to TiO2-NPs (100 mg/kg body weight). The sixth group was intragastrically administered Fuzheng Huayu (FZHY) capsules at a concentration of 4.6 g/kg body weight in addition to TiO2-NPs (100 mg/kg body weight) as the positive control group. After treatment for 4 weeks, the concentrations of lactoferrin were optimized based on the liver index and function results. Subsequently, the alleviative effects of lactoferrin interventions against TiO2-NP-induced hepatotoxicity in rat liver tissues, including the effects on histological damage, oxidative stress-related damage, inflammation, fibrosis, DNA damage, apoptosis, and gene expression, were investigated using histopathological, biochemical, and transcriptomic assays. The results showed that 200 mg/kg lactoferrin interventions for 4 weeks not only ameliorated the liver dysfunction and histopathological damage caused by TiO2-NP exposure but also inhibited the oxidative stress-related damage, inflammation, fibrosis, DNA damage, and apoptosis in the liver tissues of TiO2-NP-exposed rats. The transcriptomic results confirmed that the alleviative effect of lactoferrin interventions against the TiO2-NP exposure-induced hepatotoxicity was related to the activation of the PI3K/AKT signaling pathway.
BACKGROUND: Patients with spontaneous and traumatic intracranial hemorrhage (ICH) are frequently transfused platelets to treat thrombocytopenia, platelet function defects, and reverse antiplatelet drugs. ABO-identical platelet transfusion has been suggested to lead to higher post-transfusion platelet increments compared to major-ABO incompatible transfusion. We hypothesized that patients who received ABO-identical transfusion would have higher post-transfusion platelet increments and superior neurologic outcomes.
METHODS: Adults with traumatic or non-traumatic ICH from January 1st 2018 to December 31st 2022 were identified using electronic medical records and international classification of disease (ICD)-10 codes. Patients were excluded if they lacked a platelet count within 24 hours before and within 24 hours after transfusion or if they received multiple platelet transfusions before their platelet count was remeasured. After stratification by ABO-identical, ABO-major incompatible, and ABO-minor incompatible transfusion, post transfusion increments were compared, as were clinical outcomes.
RESULTS: Among 167 patients who received platelet transfusion, 76 (45.5%) received ABO-identical transfusion, 54 (32.3%) received ABO-major incompatible transfusion, and 37 (22.2%) received ABO-minor incompatible transfusion. There were no significant differences in absolute platelet increment between groups. The median increment was 7x109/L for ABO-identical platelets, 10x109/L for ABO-major incompatible platelets, and 11x109/L for ABO-minor incompatible platelets, p = .87. There was no significant difference in the percentage of patients discharged alive with modified Rankin score of 1 or 2 or cerebral performance category 1 or 2 between groups (p = .56 and .39 respectively). After adjusting for confounders in a general linear model there remained no associations between ABO compatibility and platelet increment after transfusion.
CONCLUSIONS: Our data support similar efficacy for ABO-identical and ABO-incompatible platelet transfusion in patients with ICH.
PURPOSE:To provide the subject preparation excellent in storage stability and easy in handling, because the capsules are not bound to each other even when the water content of a coating film is somewhat changed, and good in a disintegrating property by coating a soft capsule with a sucrose fatty acid ester. CONSTITUTION:The preparation is produced by coating a soft capsule agent with a sucrose fatty acid ester. The preparation is obtained e.g. by a method in which a commercially available sucrose fatty acid ester is treated with a 100 mesh sieve into graded fine particles and subsequently scattered on soft capsules in a coating pan with rolling the coating pan. The sucrose fatty acid ester is preferably used in an amount of 0.001-0.01wt.% per the soft capsule. The soft capsule is obtained usually by charging an oily solution, granules, powder, etc., of a medicine, a nutrition-reinforcing food, etc., in a shell formed from a coating film comprising gelatin, glycerol, sorbitol, water, etc.
BACKGROUND: Charcoal rot of soybean is caused by the hemibiotrophic fungus Macrophomina phaseolina, a global crop destroyer and an important pathogen in the midwestern USA. The quantitative nature of host resistance and the complexity of the soybean-M. phaseolina interaction at the molecular level have hampered resistance breeding. A previous study showed that L-ascorbic acid (LAA) pre-treatment before M. phaseolina inoculation reduced charcoal rot lesion length in excised soybean stems. This study aimed to elucidate the genetic underpinnings of M. phaseolina-induced senescence and the mitigating effects of ascorbic acid on this physiological process within the same pathosystem.
RESULTS: RNA was sequenced from M. phaseolina-resistant and -susceptible soybean genotypes following M. phaseolina inoculation, LAA, and hydrogen peroxide (H2O2)-an oxidative stress inducer-application followed by inoculation. More genes were down-regulated in the resistant and susceptible genotypes than up-regulated when the M. phaseolina-inoculated treatments were compared to mock-inoculated control treatments. Gene ontology (GO) term and KEGG pathways analysis detected M. phaseolina-induced up-regulation of receptor-like kinase genes. In contrast, many genes related to antioxidants, defense, and hormonal pathways were down-regulated in both genotypes. LAA pre-treatment induced genes related to photosynthesis and reactive oxygen species responses in both genotypes. H2O2 pre-treatment following inoculation up-regulated many stress-response genes, while hormone signal transduction and photosynthesis-related genes were down-regulated in both genotypes.
CONCLUSIONS: Results revealed transcriptional variation and genes associated with M. phaseolina-induced senescence in soybean. Ascorbic acid induced many photosynthetic genes, suggesting a complex regulation of defense and immunity in the plant against the hemibiotroph. Soybean plants also exhibited enhanced stress responsiveness when treated with H2O2 followed by inoculation with M. phaseolina. This study will broaden more research avenues related to transcriptional regulation during the M. phaseolina-soybean interaction and the potential role of receptor-like kinases, oxidative stress-responsive genes, ethylene-mediated signaling and enhanced photosynthetic gene expression when mounting host resistance to this important soybean pathogen.
The invention relates to cells for adoptive cell therapy, e.g., adoptive immunotherapy. The cells include macrophages in which the iPLA2β gene is disrupted. Also provided are methods and uses of the cells, such as in adoptive therapy in the treatment or prevention of type 1 diabetes (T1D). Also provided are methods for engineering, preparing, and producing the cells, and compositions containing the cells. In some aspects, the provided embodiments provide an improved composition and method for the treatment of T1D. Among the cells disclosed herein are those in which certain genes and/or gene products have been disrupted, modified and/or repressed, in particular via disruption that impairs or reduces expression of iPLA2β.
The invention discloses an irreversible vagina antibiosis gel preparation and a preparation method thereof. The vagina antibiosis gel preparation will not decrease the gel solidifying strength following the change of season or temperature. In 100ml gel preparation, the raw materials comprise 0.5 to 39.5 g chitosan, 1.5 to 23.5 g dried scallop flavor powder, 0.5 to 4.5 g wormwood flavor powder, 0.5 to 3.5 g cool gel, 0.5 to 2.5 g gelatin, and balance of purified water. The preparation method thereof comprises the steps of: mixing the raw materials in proportion, adding in purified water till reaching the required quantity, regulating ph value ranged between 5.0 and 7.0 by using acid-base regulating agent, preparing irreversible gel, and then standing by for a whole night. The vagina antibiosis gel preparation of the invention has the functions of cleaning and nursing the vagina and cervix uteri of adult women and preventing the pathological changes. After the antibiosis gel is put into the vagina, the gel will uniformly distribute on the vagina mucosa and the cervix uteri so as to kill pathopoiesia microorganisms for a long time and restrain the growing of cancer cell, lubricate the vagina and perform anti-infection and repairing functions.
BACKGROUND AND AIMS: Chronic enteropathy associated with SLCO2A1 gene is a rare intestinal disease caused by loss-of-function SLCO2A1 mutations, with clinical and genetic characteristics remaining largely unknown, especially in Chinese patients. This study aims to reveal clinical and genetic features of Chinese CEAS patients, highlighting the previously unreported or unemphasized characteristics.
METHODS: We enrolled 12 Chinese patients with chronic enteropathy associated with SLCO2A1 gene admitted to Peking Union Medical College Hospital from January 2018 to December 2022. Clinical and genetic data of these patients were collected and analyzed.
RESULTS: 58.3% of patients were male, who also had primary hypertrophic osteoarthropathy, whereas female patients did not have primary hypertrophic osteoarthropathy. Apart from common symptoms associated with anemia and hypoalbuminemia, abdominal pain, ileus, diarrhea, and hematochezia were present. 4 of the 5 female patients had early-onset amenorrhea, though the causal relationship remained to be clarified. Endoscopy and computed tomography enterography revealed that lesions can occur in any part of the digestive tract, most commonly in the ileum. Pathology showed multiple superficial ulcers with adjacent vascular dilatation, and loss of SLCO2A1 expression, particularly in gastrointestinal vascular endothelial cells. Genetic analysis confirmed SLCO2A1 mutations in all patients and identified 11 new SLCO2A1 variants for CEAS.
CONCLUSIONS: This study reports new clinical, pathological, and genetic findings in 12 Chinese patients with chronic enteropathy associated with SLCO2A1 gene. This study provides insights into the pathogenesis of this disease. However, studies with larger sample sizes and more in-depth mechanism research are still required.
PROBLEM TO BE SOLVED: To effectively prevent a patient from forgetting to take medicines. SOLUTION: A medical institution server 310 transmits prescription information showing a prescription issued to the patient and patient information to a center 100 through a communication network 10. The center 10 accumulates prescription information and patient information, which are received from the medical institution server 310. The center 100 transmits prescription information to a pharmacy server 510 in accordance with a request from the pharmacy server 510 and generates taking schedule information based on the prescription. The center 100 transmits the effect to the mobile terminal 720 of the patient at the taking period of the medicine based on generated taking schedule information. When there is the possibility of adverse effect by the medicine, the center 100 transmits the effect to the mobile terminal 720.
ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules). Open-label Treatment in Run-in 2 for 4-6 weeks.
Mass spectrometry imaging (MSI) is a powerful scientific tool for understanding the spatial distribution of biochemical compounds in tissue structures. In this paper, we introduce three novel approaches in MSI data processing to perform the tasks of data augmentation, feature ranking, and image registration. We use these approaches in conjunction with non-negative matrix factorization (NMF) to resolve two of the biggest challenges in MSI data analysis, namely: 1) the large file sizes and associated computational resource requirements and 2) the complexity of interpreting the very high dimensional raw spectral data. There are many dimensionality reduction techniques that address the first challenge but do not necessarily result in readily interpretable features, leaving the second challenge unaddressed. We demonstrate that NMF is an effective dimensionality reduction algorithm that reduces the size of MSI datasets by three orders of magnitude with limited loss of information, yielding spatial and spectral components with meaningful correlation to tissue structure that may be used directly for subsequent data analysis without the need for additional clustering steps. This analysis is demonstrated on an MSI dataset from female Sprague-Dawley rats for an animal model of comorbid visceral pain hypersensitivity (CPH). We find that high-dimensional MSI data (∼ 100,000 ions per pixel) can be reduced to 20 spectral NMF components with < 20% loss in reconstruction accuracy. The resulting spatial NMF components are reproducible and correlate well with H&E-stained tissue images. These components may also be used to generate images with enhanced specificity for different tissue types. Small patches of NMF data (i.e., 20 spatial NMF components over 20 × 20 pixels) provide an accuracy of ∼ 87% in classifying CPH vs naïve control subjects. This paper presents the novel data processing methodologies that were used to produce these results, encompassing novel data processing pipelines for data augmentation to support training for classification, ranking of features according to their contribution to classification, and image registration to enhance tissue-specific imaging.
PURPOSE: To investigate the clinical performance, pathological characteristics, treatment and prognosis of salivary gland malignant tumor (SGMT) with skull base metastasis.
METHODS: Five SGMT patients with skull base metastasis were retrospectively studied. Major clinical symptoms included headache, facial paralysis, and ear hearing loss. Three patients had previous history of SGMT resection. All patients underwent preoperative computed tomography (CT) and magnetic resonance imaging (MRI). Craniotomy was performed in three patients, and all the five patients underwent radiotherapy and chemotherapy.
RESULTS: Two patients were confirmed as having adenocarcinoma, one patient was pathologically confirmed to have squamous cell carcinoma, one patient had ductal carcinoma, and one patient had acinar cell carcinoma. One patient died after 2 years of treatment, and the remaining 4 patients were followed up for 6 ∼ 24 months, suggesting that the tumor size was not enlarged or showed no local recurrence.
CONCLUSION: SGMT with skull base metastasis is extremely rare, and due to similar imaging characteristics, it can be easily misdiagnosed as meningioma or schwannoma. Early diagnosis, extent of invasion, surgery and combination of chemotherapy and radiotherapy are the prognostic factors of the disease.
To explore the effect of hypoproteinemia on cardiac function and prognosis in elderly male patients with chronic heart failure. Among the patients with chronic heart failure hospitalized in the General Hospital of Southern Theater Command from December 2014 to December 2015, 100 elderly male patients with chronic heart failure were selected. The patients were divided into 2 groups based on their serum albumin (ALB) levels: 53 cases in the normal group (ALB ≥ 35 g/L) and 47 cases in the hypoproteinemia group (ALB < 35 g/L). Using the method of prospective study, under the condition of routine treatment of heart failure, follow-up observation for 5 years, we collected relevant data and analyzed the level of serum ALB, cardiac function and prognosis of patients in these 2 groups. The mortality of patients in the hyporoteinemia group were significantly higher than those in the normal group. Left ventricular end-diastolic dimension (LVDD) and brain natriuretic peptide (BNP) in the normal group after 5 years were markedly lower compared with that in the hypoproteinemia group. The mortality of patients with chronic heart failure with hypoproteinemia were higher, and the present study indicated that the ALB level may be associated with the mortality of patients with chronic heart failure.
The invention relates to a traditional Chinese medicine for treating anorexia. The traditional Chinese medicine can be used for effectively solving the problem that the anorexia in children is long in treatment period, poor in treatment effect and easily relapses. The traditional Chinese medicine for treating anorexia is prepared from the following medicinal raw materials by weight: 8-10g of codonopsis pilosula, 11-13g of Chinese yams, 5-7g of fructus amomi, 11-13g of coix seeds, 11-13g of chicken's gizzard-membranes, 8-10g of fructus aurantii, 11-13g of white atractylodes rhizome, 8-10g of poia cocos, 8-10g of dried tangerine or orange peel, 11-13g of roasted malts, 11-13g of hawthorns, 11-13g of medicated leaven, 11-13g of oysters, 8-10g of pangolins and 8-10g of tortoise plastron. A preparation method of the traditional Chinese medicine for treating anorexia comprises the following steps: mixing the medicinal raw materials, adding water to immerse the medicinal raw materials, decocting, firstly boiling with strong fire, then decocting with slow fire, filtering to obtain primary decoction; adding water to immerse dregs, boiling the dregs with strong fire, then, decocting the dregs with slow fire, and filtering to obtain secondary decoction; and mixing the decoctions to obtain the traditional Chinese medicine for treating anorexia. The traditional Chinese medicine for treating anorexia is scientific in compatibility of medicinal raw materials, simple in preparation method, short in treatment period, good in effect, free of side effect. Anorexia hardly relapses, and therefore, the traditional Chinese medicine for treating anorexia is a creation in the traditional Chinese medicine.
Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
PURPOSE:To improve the emulsified state of an emulsified compsn. and the stability over a long period by blending an adduct of polyoxyethylene to >=22C higher alcohol with lower alcohol and an oil component to prepare the emulsified compsn. CONSTITUTION:The adduct of polyoxyethylene to >=22C higher alcohol is blended with lower alcohol and the oil component or further blended with additives such as a thickener, an org. pigment and a fungicide to prepare an emulsified compsn. the higher alcohol may be behenyl alcohol or carnaubyl alcohol and about 1-30mol polyoxyethylene is preferably added to the higher alcohol. The lower alcohol is <=5C alcohol and the pref. amt. of the lower alcohol used is 5-40wt.%. The oil component may be selected among fats, oils, waxes and hydrocarbons and the pref. amt. of the oil component used is 0.5-80wt.%.
The present invention relates to externally used ointment for treating burn and scald and a preparation method thereof. The ointment is a medicine preparation which is composed of the following raw materials of 50 to 150 portions of head coal, 5 to 10 portions of borneol, 10 to 15 portions of vaseline oil and 30 to 35 portions of beeswax by a weight proportion. Head coal adopts coal with the ash content of lower than 8% in weight percentage and the sulfur content of lower than 0.6% in weight percentage. The present invention has the advantages of simple recipe and novel and peculiar idea of the externally used ointment for treating burn and scald of the present invention. The present invention which uses common head coal as main ingredients for treating burn and scald can obtain the functions of absorption of apostasis water content, detumescence and relief of inflammation. The main ingredients are common head coal, and the cost is low. The ointment is formed by preparation of ore materials and traditional Chinese medicinal materials, and has the advantages of convenient manufacture, simple and easy obtainment of materials and outstanding curative effects. The present invention is an easily accepted product by urban and rural people, and has the characteristics of fast effect and no scar.
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be performed with a lower total dose of local anesthesia (and greater patient safety) when using 0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine. Mohs micrographic surgery is a multi-staged, same-day procedure used to remove skin cancers under local anesthesia. Reconstruction of the surgical wound is also performed under local anesthesia, usually immediately after achieving tumor clearance.

This randomized, double-blind study will systematically compare the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% of lidocaine with 1:200,000 epinephrine needed to achieve local anesthesia during Mohs micrographic surgery (MMS). All healthy adult volunteers (18 years or older) undergoing Mohs micrographic surgery at the Hospital of the University of Pennsylvania's Department of Dermatology and Dermatologic Surgery between June 1, 2007 and August 31, 2007 will be eligible to participate in the study. Our primary intervention will be to record the total dose of lidocaine administered throughout all of the MMS stages and reconstructions using either of the two lidocaine concentrations. A secondary intervention will be to record each patient's level of pain control in order to demonstrate that patient comfort is effectively achieved with a lower total dose of local anesthesia. Pregnant or breast-feeding subjects, those with a history of allergic or other adverse reaction to lidocaine or epinephrine, and those who are cognitively impaired will be excluded. In addition, if the surgeon believes that a patient has a tumor which, due to size or anatomic site, may put him at risk for requiring a dose of lidocaine that approaches the threshold of toxicity, this patient will be excluded from the study.
In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.